RT Journal Article
T1 Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020).
T2 Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020).
A1 Rodríguez, Manuel
A1 Buti, María
A1 Esteban, Rafael
A1 Lens, Sabela
A1 Prieto, Martín
A1 Suárez, Emilio
A1 García-Samaniego, Javier
K1 ADN-VHB
K1 AEEH document
K1 Documento de la AEEH
K1 Entecavir
K1 HBV-DNA
K1 HBsAg
K1 Hepatitis B
K1 Hepatocarcinoma
K1 Hepatocellular carcinoma
K1 Interferon
K1 Interferón
K1 Tenofovir
K1 Tenofovir alafenamida
K1 Tenofovir alafenamide
AB Hepatitis B virus (HBV) infection remains a global public health problem. HBV vaccination is the most effective tool to reduce the incidence of HBV disease. Despite there has not been new clinical developments for the treatment of chronic hepatitis B in the last few years, changing epidemiology and current insights on natural history, diagnostic tools and therapy indications make necessary an update of the former version of the consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B infection published in 2012. The current document updates the management of chronic hepatitis B. The treatment of choice is the long-term administration of a nucleos(t)ide analogue with high barrier to resistance (entecavir, tenofovir or tenofovir alafenamide). Pegylated interferon may be an option in patients with non-advanced liver disease, but its applicability is limited due to the low efficacy and poor tolerability. All patients must be monitored for the risk of progression to advanced liver disease and development of hepatocellular carcinoma.
SN 0210-5705
YR 2020
FD 2020-08-07
LK http://hdl.handle.net/10668/16084
UL http://hdl.handle.net/10668/16084
LA en
LA es
DS RISalud
RD Feb 18, 2025